Looking into Macrogenics’s Return on Capital Employed
After pulling data from Benzinga Pro it seems like during Q2, Macrogenics's (NASDAQ:MGNX) reported sales totaled $30.76 million. Despite a 21.47% in earnings, the company posted a loss of $40.28 million.
Earnings Scheduled For July 29, 2021
Companies Reporting Before The Bell
• Smith & Nephew (NYSE:SNN) is projected to report earnings for its second quarter.
MacroGenics, Zai Lab Ink Over $1.4B Immuno-Oncology Development Deal
MacroGenics Inc (NASDAQ:MGNX) and Zai Lab Limited (NASDAQ:ZLAB) have entered into an exclusive collaboration and license agreement involving up to four immuno-oncology molecules.…
MacroGenics And Zai Lab Enter Collaboration To Develop And Commercialize Preclinical Bispecific Antibodies in Oncology; MacroGenics To Receive Initial Consideration Of $55M, An Equity Investment And Is Eligible For $1.4B In Milestones
Zai Lab granted combination of regional Asian and global rights for up to four CD3- or CD47-based bispecific molecules
MacroGenics provides rights to Zai Lab for its DART® and TRIDENT® multi-specific platforms
40 Stocks Moving In Friday’s Mid-Day Session
Gainers
SemiLEDs Corporation (NASDAQ: LEDS) shares jumped 68.8% to $25.49 after gaining 23% on Thursday.
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-specific news flow dictated stock moves during the week.
Pharma/Biotech Companies Highlight Upcoming Presentations At American Society Of Clinical Oncology Jun. 4-8, 2021
Cullinan Oncology (CGEM) - https://www.globenewswire.com/news-release/2021/05/19/2232874/0/en/Cullinan-Oncology-to-Provide-CLN-081-Clinical-Update-at-ASCO-2021.html
BeiGene (BGNE)